
|Articles|April 15, 2008
Provectus gains patent allowance for PH-10 in the EU
Knoxville, Tenn. - Provectus Pharmaceuticals has received allowance of its patent application in the European Union to cover PH-10, as well as other related agents and their use, Businesswire reports.
Advertisement
Knoxville, Tenn.
- Provectus Pharmceuticals has received allowance of its patent application in the European Union for PH-10, as well as other related agents and their use, according to Businesswire.
The pending patents cover topical applications for treatment of psoriasis and eczema. Currently, PH-10 is undergoing a phase 2 clinical trial in New York City for the treatment of moderate to severe psoriasis, Businesswire reports.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
CSU With Biochemical C1 Inhibitor Deficiency: Case Report Raises Diagnostic Questions
2
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
3
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
4
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
5











